(AIM:REDX) Compelling opportunity to take targeted oncology and fibrosis medicines into the clinic Corporate Presentation August 2020
Disclaimer The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under the securities laws of any state or other jurisdiction of the United States (within the meaning of Regulation S under the Securities Act), and may not be offered or sold into or within the United States absent registration under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Subject to certain limited exceptions, neither this presentation nor any copy of it may be taken, transmitted or distributed, directly or indirectly, in or into the United States. Neither this presentation nor any copy of it or any of the presentation may be taken or transmitted into or distributed in Canada, Australia, or the Republic of South Africa or to any resident thereof, or taken or transmitted into or distributed in Japan or to any resident thereof or to any other jurisdiction which prohibits such taking in, transmission or distribution, except in compliance with applicable securities laws. Any failure to comply with these restrictions may constitute a violation of the securities laws or the laws of any such jurisdiction. The distribution of this document in other jurisdictions may be restricted by law and the persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with this and the above restriction may constitute a violation of United States or other national securities laws. Recipients of this presentation are not to construe its contents, or any prior or subsequent communications from or with the Company or its representatives as investment, legal or tax advice. In addition, this presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of any transaction. Further, the information in this presentation is not complete and may be changed. Recipients of this presentation should each make their own independent evaluation of the information and of the relevance and adequacy of the information in this presentation and should make such other investigations as they deem necessary. Accordingly no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation and no reliance should be placed on such information or opinions. None of the Company, or any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this presentation. No part of this presentation, or the fact of its distribution, should form the basis of or be relied upon in connection with any contract or commitment or investment decision whatsoever. This presentation does not form part of any offer of securities, or constitute a solicitation of any offer to purchase or subscribe for securities or an inducement to enter into any investment activity. This Presentation includes forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties, many of which are beyond the Company's control and all of which are based on the Directors' current beliefs and expectations about future events. Forward-looking statements are sometimes identified by the use of forward-looking terminology such as "believe", "expects", "may", "will", "could", "should", "shall", "risk", "intends", "estimates", "aims", "plans", "predicts", "continues", "assumes", "positioned", "targets" or "anticipates" or the negative thereof, other variations thereon or comparable terminology. These forward- looking statements include all matters that are not historical facts. They appear in a number of places throughout this presentation and include statements regarding the intentions, beliefs or current expectations of the Directors or the Company concerning, among other things, the results of operations, financial condition, prospects, growth, strategies, and dividend policy of the Company and the industry in which it operates. These forward- looking statements and other statements contained in this presentation regarding matters that are not historical facts involve predictions. No assurance can be given that such future results will be achieved; actual events or results may differ materially as a result of risks and uncertainties facing the Company. Such risks and uncertainties could cause actual results to vary materially from the future results indicated, expressed, or implied in such forward-looking statements. Such forward-looking statements contained in this presentation speak only as of the date of this presentation. The Company and the Directors expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this presentation to reflect any change in their expectations or any change in events, conditions or circumstances on which such statements are based unless required to do so by applicable law or the AIM Rules for Companies. By participating in this presentation and/or accepting any copies hereof you agree to be bound by the foregoing restrictions and the other terms of this disclaimer. General Use Disclaimer updated Aug 2020 Redx Pharma Corporate Presentation - August 2020 2
Redx Pharma Overview Biotech focused on small molecule, targeted medicines in oncology and fibrosis • Targeting compelling op opportunities in dis isease ar areas wit ith hig high unmet ne need an and str trong sc scie ientific rationale • Hig ighly experienced in-house res esearch te team wit ith pr proven track record built on on medicinal ch chemistry ry expertise − 2017 Sale to Loxo Oncology/Eli Lilly of BTK inhibitor (now LOXO-305) for $40M cash; entered Phase 2 clinical trials − 2019 Sale to Jazz Pharmaceuticals of pan-RAF inhibitor for $3.5M with up to $203M in milestones, plus royalties − 2020 Out Licensing agreement with AstraZeneca for porcupine inhibitor RXC006 targeting fibrosis for $17m in early payments with up to $360 in milestones, plus royalties • In In on oncology, , RX RXC004 ha has op opportunity to un unlock po potential of of th the Wnt pa pathway in in genetically sele selected pa patients − RXC004 Phase 1 monotherapy dose-escalation study completing in 2020, building on compelling animal efficacy data − Targeted at tumours driven by Wnt pathway in multiple cancers – both monotherapy and immuno-oncology combination − Therapeutic window for class now evident (120+ patients in clinical trials) with early signs of efficacy in targeted patients • In In fib fibrosis is, ROCK2 is s an an excitin ing target in n mult ltiple fib fibrotic dise disease ses with th RX RXC0 C007 pla planned to to en enter cl clin inic in 2021 2021 − RXC007 as a ROCK2 selective inhibitor was nominated as a preclinical development candidate in H1 2020 − Promising preclinical efficacy and targets significant commercial markets (IPF, NASH, diabetic nephropathy) with limited competition in ROCK2 pathway − ROCK2 inhibitor belumosudil (KD025) by Kadmon is well tolerated in >450 patients in clinical trials, with clinical anti-fibrotic activity in IPF and compelling efficacy in cGvHD demonstrated IPF IPF = Idiopathic Pulmonary Fibrosis; NAS NASH = Non-alcoholic Steatohepatitis; cGvH GvHD = chronic Graft versus Host Disease Redx Pharma Corporate Presentation - August 2020 3
Redx Executive Management Team Ambitious Management team in place with strong scientific, clinical and commercial experience June 2014 Lisa Anson, Dr Richard Armer, 2018 Chief Executive Officer Chief Scientific Officer 20-year career at AstraZeneca plc. Significant experience in both small biotech Significant leadership experience and large pharmaceutical companies through including President of AstraZeneca UK, roles in Pfizer, Organon, Ardana, Oxagen & President of the Association of British Lectus Therapeutics. Successful in generating Pharmaceutical Industry and progressing multiple clinical candidates Dr Andrew Saunders, Dr James Mead, Jan Feb 2018 2019 Chief Medical Officer Chief Financial Officer Oncology focus since 1992 both in Finance leadership roles with 16 years at clinical practice and pharmaceutical/ AstraZeneca, including CFO AstraZeneca biotech industry. Including senior roles Netherlands and Investor Relations; at Eli-Lilly and Roche (Rituximab) PhD in molecular biology Redx Pharma Corporate Presentation - August 2020 4
Recommend
More recommend
